Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HILS NYSE:IBIO NYSE:NNVC NASDAQ:NTEC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHILSHillstream BioPharma$1.63-3.0%$1.54$0.19▼$2.65$28.69M3.081.39 million shs45,536 shsIBIOiBio$0.73+0.1%$0.81$0.64▼$6.89$12.08M0.94872,812 shs678,521 shsNNVCNanoViricides$1.68+2.4%$1.46$0.94▼$2.55$27.00M0.88235,767 shs250,304 shsNTECIntec Pharma$13.52$8.80▼$36.88$8.65M0.83543,436 shs988,300 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHILSHillstream BioPharma-2.98%-3.56%+23.48%+41.74%-61.37%IBIOiBio-0.27%-11.52%-10.41%-17.98%-66.05%NNVCNanoViricides+2.50%+16.31%+22.39%+23.31%-27.43%NTECIntec Pharma0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHILSHillstream BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AIBIOiBio1.2865 of 5 stars3.50.00.00.00.60.00.6NNVCNanoViricides0.3736 of 5 stars0.03.00.00.03.10.00.0NTECIntec PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHILSHillstream BioPharma 0.00N/AN/AN/AIBIOiBio 3.00Buy$4.30488.24% UpsideNNVCNanoViricides 0.00N/AN/AN/ANTECIntec Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NTEC, HILS, NNVC, and IBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.005/5/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHILSHillstream BioPharmaN/AN/AN/AN/A$0.48 per shareN/AIBIOiBio$375K32.20N/AN/A$1.41 per share0.52NNVCNanoViricidesN/AN/AN/AN/A$0.66 per shareN/ANTECIntec PharmaN/AN/AN/AN/A$16.18 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHILSHillstream BioPharma-$8.47M-$0.72N/AN/AN/AN/A-188.44%-149.61%N/AIBIOiBio-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/ANNVCNanoViricides-$8.29M-$0.70N/A∞N/AN/A-87.90%-78.69%N/ANTECIntec Pharma-$14.13M-$16.32N/AN/AN/AN/A-96.37%-68.87%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHILSHillstream BioPharmaN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/ANNVCNanoViricidesN/AN/AN/AN/AN/ANTECIntec PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHILSHillstream BioPharmaN/A3.013.01IBIOiBio0.051.761.76NNVCNanoViricidesN/A3.442.47NTECIntec PharmaN/A2.342.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHILSHillstream BioPharma13.36%IBIOiBio7.90%NNVCNanoViricides10.30%NTECIntec Pharma22.37%Insider OwnershipCompanyInsider OwnershipHILSHillstream BioPharma30.24%IBIOiBio0.58%NNVCNanoViricides4.60%NTECIntec Pharma3.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHILSHillstream BioPharma117.60 million12.28 millionNot OptionableIBIOiBio10016.52 million9.82 millionN/ANNVCNanoViricides2016.07 million14.92 millionOptionableNTECIntec Pharma40898,000N/AOptionableNTEC, HILS, NNVC, and IBIO HeadlinesRecent News About These CompaniesINDP stock touches 52-week low at $0.78 amid market challengesFebruary 12, 2025 | msn.comIndaptus Therapeutics reports Q3 EPS (32c) vs. (47c) last yearNovember 13, 2024 | markets.businessinsider.comFinTechOn 2024: FinTech Associations from 14 Asian Economies Sign MOU to Enhance Collaborations in Anti-FraudNovember 5, 2024 | finance.yahoo.comX4 Pharmaceuticals, Inc. (XFOR)September 21, 2024 | finance.yahoo.comIntec Pharma shares dive after Parkinson's trial failureSeptember 9, 2024 | pharmaphorum.comPINDP Indaptus Therapeutics, Inc.August 23, 2024 | seekingalpha.comQ1 Results, Aug. 14: Ola Electric, Glenmark, HAL To Declare Earnings TodayAugust 14, 2024 | ndtvprofit.comNBuy Rating Affirmed for Indaptus Therapeutics Amid Positive Decoy20 Clinical DevelopmentsAugust 13, 2024 | markets.businessinsider.comMorepen Laboratories Ltd Company SummaryJuly 22, 2024 | indiainfoline.comIWill Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs InMay 14, 2024 | msn.comMinebea Intec Opens Technical CenterMay 10, 2024 | powderbulksolids.comPBuy Rating Affirmed for Indaptus Therapeutics Amid Promising Decoy20 Clinical AdvancementsMay 10, 2024 | markets.businessinsider.comRheinmetall’s MS Motorservice Implements State-of-the-Art High-Bay Storage System in NeuenstadtApril 17, 2024 | news.europawire.euNBuy Rating Affirmed for Indaptus Therapeutics Amid Positive Clinical and Financial OutlookMarch 15, 2024 | markets.businessinsider.comBuy Rating Affirmed on Indaptus Therapeutics as Decoy20 Advances in Phase 1 with Promising DevelopmentsMarch 6, 2024 | markets.businessinsider.comStocks to Watch Today: RVNL,Glenmark Pharma, PB Fintech,Sula Vineyards and moreFebruary 18, 2024 | msn.comChhattisgarh education minister calls for expansion of central schools in the stateFebruary 2, 2024 | msn.comThe 2024 Chicago Titan 100: Here's who made the listNovember 12, 2023 | dailyherald.comDH.C. Wainwright Sticks to Its Buy Rating for Indaptus Therapeutics (INDP)August 15, 2023 | markets.businessinsider.comNGENF - NervGen Pharma Corp.June 15, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseChime Financial: Analysts Ring In—And It’s a BuyBy Thomas Hughes | July 9, 2025View Chime Financial: Analysts Ring In—And It’s a BuyNTEC, HILS, NNVC, and IBIO Company DescriptionsHillstream BioPharma NASDAQ:HILS$1.63 -0.05 (-2.98%) As of 07/16/2025Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.iBio NYSE:IBIO$0.73 +0.00 (+0.14%) Closing price 04:00 PM EasternExtended Trading$0.72 -0.01 (-0.96%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.NanoViricides NYSE:NNVC$1.68 +0.04 (+2.44%) Closing price 04:00 PM EasternExtended Trading$1.59 -0.09 (-5.30%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.Intec Pharma NASDAQ:NTECIntec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
